Nuwe Cleveland Clinic-navorsing toon vir die eerste keer dat FDA-goedgekeurde ibrutinib (ibrutinib) vir limfoom en leukemie ook kan help om die mees algemene en dodelike breingewasse te behandel, en kan eendag by pasiënte met glioblastoom gebruik word en oorlewingsyfers verbeter.
Volgens die verslag van die American Brain Tumor Association is die oorlewingsyfer van glioblastoom baie laag, en die mediaan oorlewing van pasiënte wat standaardbehandeling ontvang is minder as 15 maande. Glioblastoom is die mees dodelike primêre breingewas en is hoogs bestand teen huidige behandelings. Daar is 'n dringende behoefte om hierdie pasiënte so gou moontlik van nuwe behandelings te voorsien.
In an earlier study, Bao and colleagues found that glioom stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain gewasse in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
